Clinical trials Brief October 19, 2026, 10:02 AM ET

Eli Lilly registers Phase 3 study of EloraTZP in obesity and type 2 diabetes

The study plans to enroll 1000 participants, start in November 2026, and reach primary completion in October 2029. It aims to investigate the efficacy and safety of the eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide in adults with obesity or overweight and type 2 diabetes.

Primary source

ClinicalTrials.gov registry record, October 19, 2026

A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes

Read the source: A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes clinicaltrials.gov

By The Priority Review desk. Machine-summarized from the source above; not independently reported. How we use automation